In vivo positron emission tomography imaging of protease activity by generation of a hydrophobic product from a noninhibitory protease substrate

Clinical Cancer Research

Volumn 18, Issue 1, 2012, Pages 238-247

  Chuang, Chih Hung ^a   Chuang, Kuo Hsiang ^b   Wang, Hsin Ell ^e   Roffler, Steve R ^f   Shiea, Jen Taie ^c   Tzou, Shey Cherng ^b   Cheng, Ta Chun ^b   Kao, Chien Han ^b   Wu, Shih Yen ^e   Tseng, Wei Lung ^c   Cheng, Chiu Min ^d   Hou, Ming Feng ^b   Wang, Ju Ming ^a   Cheng, Tian Lu ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^d NATIONAL KAOHSIUNG UNIVERSITY OF APPLIED SCIENCES   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE 18; GELATINASE A; GELATINASE B; MACROGOL; PROTEINASE; TETRAMETHYLRHODAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HALF LIFE TIME; HUMAN; HUMAN CELL; HYDROLYSIS; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DIAGNOSTIC IMAGING; FEMALE; FIBROSARCOMA; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MATRIX METALLOPROTEINASE INHIBITORS; MICE; MICE, INBRED BALB C; MICE, NUDE; PEPTIDE FRAGMENTS; POLYETHYLENE GLYCOLS; POSITRON-EMISSION TOMOGRAPHY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TISSUE DISTRIBUTION;

EID: 84855423104     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0608     Document Type: Article

References (46)

1. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, et al. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993;53:5365-9. (Pubitemid 23342150)
2. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003;3:489-501. (Pubitemid 37328837)
3. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000;10:415-33. (Pubitemid 32181912)
4. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 2004;48:411-24. (Pubitemid 39360392)
5. He Y, Liu XD, Chen ZY, Zhu J, Xiong Y, Li K, et al. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis. Clin Cancer Res 2007;13:3115-24. (Pubitemid 46944892)
6. Parsons SL, Watson SA, Steele RJ. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol 1997;23:526-31. (Pubitemid 28059777)
7. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-49. (Pubitemid 30123793)
8. Chiappori AA, Eckhardt SG, Bukowski R, Sullivan DM, Ikeda M, Yano Y, et al. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res 2007;13:2091-9. (Pubitemid 46649877)
9. Beattie GJ, Smyth JF. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 1998;4:1899-902. (Pubitemid 28369173)
10. Albright CF, Graciani N, Han W, Yue E, Stein R, Lai Z, et al. Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity. Mol Cancer Ther 2005;4:751-60. (Pubitemid 40767119)
11. Stern L, Perry R, Ofek P, Many A, Shabat D, Satchi-Fainaro R. A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain. Bioconjug Chem 2009;20:500-10.
12. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009;27:5287-97.
13. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002;99:157-66. (Pubitemid 34309470)
14. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 2001;7:3113-9. (Pubitemid 32963832)
15. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A 2004;101:17867-72. (Pubitemid 40051978)
16. Law B, Curino A, Bugge TH, Weissleder R, Tung CH. Design, synthesis, and characterization of urokinase plasminogen-activator-sensitive near-infrared reporter. Chem Biol 2004;11:99-106. (Pubitemid 38203994)
17. Bremer C, Tung CH, Bogdanov A Jr, Weissleder R. Imaging of differential protease expression in breast cancers for detection of aggressive tumor phenotypes. Radiology 2002;222:814-8. (Pubitemid 34218157)
18. Jastrzebska B, Lebel R, Therriault H, McIntyre JO, Escher E, Guerin B, et al. New enzyme-activated solubility-switchable contrast agent for magnetic resonance imaging: from synthesis to in vivo imaging. J Med Chem 2009;52:1576-81.
19. Wagner S, Breyholz HJ, Law MP, Faust A, Holtke C, Schroer S, et al. Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3- methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET. J Med Chem 2007;50:5752-64. (Pubitemid 350106030)
20. Zheng QH, Fei X, DeGrado TR, Wang JQ, Stone KL, Martinez TD, et al. Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-[[4-(6-fluorohex-1-ynyl)phenyl] sulfonylamino]-3-methylbutyric acid [11C]methyl ester. Nucl Med Biol 2003;30:753-60. (Pubitemid 37123133)
21. Watkins GA, Jones EF, Scott Shell M, VanBrocklin HF, Pan MH, Hanrahan SM, et al. Development of an optimized activatable MMP-14 targeted SPECT imaging probe. Bioorg Med Chem 2009;17:653-9.
22. Bae M, Cho S, Song J, Lee GY, Kim K, Yang J, et al. Metalloprotease- specific poly(ethylene glycol) methyl ether-peptide-doxorubicin conjugate for targeting anticancer drug delivery based on angiogenesis. Drugs Exp Clin Res 2003;29:15-23. (Pubitemid 36818532)
23. Fiore E, Fusco C, Romero P, Stamenkovic I. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 2002;21:5213-23. (Pubitemid 34948133)
24. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 1998;58:1395-9. (Pubitemid 28193598)
25. Wust F, Hultsch C, Bergmann R, Johannsen B, Henle T. Radiolabelling of isopeptide N epsilon-(gamma-glutamyl)-L-lysine by conjugation with N-succinimidyl-4-[18F]fluorobenzoate. Appl Radiat Isot 2003;59:43-8. (Pubitemid 37303984)
26. Bremer C, Bredow S, Mahmood U, Weissleder R, Tung CH. Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology 2001;221:523-9. (Pubitemid 33043440)
27. Koga Y, Yasunaga M, Moriya Y, Akasu T, Fujita S, Yamamoto S, et al. Detection of colorectal cancer cells from feces using quantitative real-time RT-PCR for colorectal cancer diagnosis. Cancer Sci 2008;99:1977-83.
28. Walton TJ, Li G, McCulloch TA, Seth R, Powe DG, Bishop MC, et al. Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue. Prostate 2009;69:810-9.
29. Zhang B, Cao X, Liu Y, Cao W, Zhang F, Zhang S, et al. Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer. BMC Cancer 2008;8:83.
30. Ward AM, Catto JW, Hamdy FC. Prostate specific antigen: biology, biochemistry and available commercial assays. Ann Clin Biochem 2001;38:633-51. (Pubitemid 33702270)
31. Ujula T, Huttunen M, Luoto P, Perakyla H, Simpura I, Wilson I, et al. Matrix metalloproteinase 9 targeting peptides: syntheses, 68Ga-labeling, and preliminary evaluation in a rat melanoma xenograft model. Bioconjug Chem 2010;21:1612-21.
32. Jaffer FA, Vinegoni C, John MC, Aikawa E, Gold HK, Finn AV, et al. Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation 2008;118:1802-9.
33. Fuse T, Watanabe K, Kitazato K, Kobayashi N. Establishment of a new cell line inducibly expressing HIV-1 protease for performing safe and highly sensitive screening of HIV protease inhibitors. Microbes Infect 2006;8:1783-9. (Pubitemid 44128880)
34. Lei YF, Yin W, Yang J, Lv X, Wei SH, An QX, et al. Development of a cell-based assay for monitoring hepatitis C virus ns3/4a protease activity. Acta Virol 2008;52:133-41.
35. Chen J, Tung CH, Allport JR, Chen S, Weissleder R, Huang PL. Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation 2005;111:1800-5. (Pubitemid 40525145)
36. Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA, et al. Arthritis critically dependent on innate immune system players. Immunity 2002;16:157-68. (Pubitemid 34211957)
37. Madsen MT, Park CH. Enhancement of SPECT images by Fourier filtering the projection image set. J Nucl Med 1985;26:395-402. (Pubitemid 16192350)
38. Sprague JE, Li WP, Liang K, Achilefu S, Anderson CJ. In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models. Nucl Med Biol 2006;33:227-37.
39. Oltenfreiter R, Staelens L, Kersemans V, Cornelissen B, Frankenne F, Foidart JM, et al. Valine-based biphenylsulphonamide matrix metalloproteinase inhibitors as tumor imaging agents. Appl Radiat Isot 2006;64:677-85.
40. Kulasegaram R, Giersing B, Page CJ, Blower PJ, Williamson RA, Peters BS, et al. In vivo evaluation of 111In-DTPA-N-TIMP-2 in Kaposi sarcoma associated with HIV infection. Eur J Nucl Med 2001;28:756-61.
41. Wagner S, Breyholz HJ, Faust A, Holtke C, Levkau B, Schober O, et al. Molecular imaging of matrix metalloproteinases in vivo using small molecule inhibitors for SPECT and PET. Curr Med Chem 2006;13:2819-38. (Pubitemid 44509727)
42. Yang Y, Hong H, Zhang Y, Cai W. Molecular imaging of proteases in cancer. Cancer Growth Metastasis 2009;2:13-27.
43. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92. (Pubitemid 34270240)
44. DiPaola RS, Rinehart J, Nemunaitis J, Ebbinghaus S, Rubin E, Capanna T, et al. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J Clin Oncol 2002;20:1874-9. (Pubitemid 34273279)
45. Mhaka A, Denmeade SR, Yao W, Isaacs JT, Khan SR. A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer. Bioorg Med Chem Lett 2002;12:2459-61. (Pubitemid 34879890)
46. Rothenberg ML, Carbone DP, Johnson DH. Improving the evaluation of new cancer treatments: challenges and opportunities. Nat Rev Cancer 2003;3:303-9. (Pubitemid 37328866)